Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Indomethacin  COVID-19 treatment studies for Indomethacin  C19 studies: Indomethacin  Indomethacin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Ventilation 66% Improvement Relative Risk Recovery time -40% c19early.com/in Salmasi et al. IRCT20200427047215N1 Indomethacin RCT LATE Favors indomethacin Favors control
Salmasi, 45 patient indomethacin late treatment RCT: 66% lower ventilation [p=1] and 40% slower recovery [p=0.52] https://c19p.org/salmasi
copied to clipboard
Efficacy of oral indomethacin in the treatment of COVID-19 infection; a randomized clinical trial
Salmasi et al., Immunopathologia Persa, doi:10.34172/ipp.2022.xx, IRCT20200427047215N1
13 Jan 2022    Source   PDF   Share   Tweet
Very small RCT with 22 indomethacin and 23 control patients, showing no significant difference in outcomes. All patients were treated with HCQ.
risk of mechanical ventilation, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 22 (0.0%), control 1 of 23 (4.3%), NNT 23, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 40.0% higher, relative time 1.40, p = 0.52, treatment 22, control 23.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Salmasi et al., 13 Jan 2022, Randomized Controlled Trial, Iran, peer-reviewed, 8 authors, trial IRCT20200427047215N1.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIndomethacinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit